Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single, Three, Five Injection), By End-use (Hospitals, Orthopedic Clinics/ASCs), By Region (Asia Pacific, Europe), And Segment Forecasts, 2021 - 2028

Report Overview

The global viscosupplementation market size was valued at USD 3.76 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.37% from 2021 to 2028. The increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market. Viscosupplements available in the market have shown clinical efficacy and are proven to be the most effective treatment for knee osteoarthritis. Osteoarthritis is a chronic painful degenerative joint disease and is the leading cause of chronic disability. The onset of the condition is mostly after 30 years of age, which may progress to develop into a disability after 10 years of diagnosis.

Estimates published by the WHO suggest that the global population aged 65 years and over is projected to increase from 7% in 2000 to 16% in 2050, which, in turn, will lead to a rise in the incidence of obesity and osteoarthritis. Thus, the global increase in the target population along with a growing preference for alternative treatment options for corticosteroid for joint pain management is expected to significantly propel the product demand during the forecast period.

The reimbursement scenario is likely to become favorable globally making treatment for osteoarthritis affordable. In the U.S., products, such as Orthovisc, Supartz Hyalgan, Synvisc, and others, are approved by the FDA as Class III medical devices to treat OA knee pain and are reimbursed by Medicaid, Medicare, and other state healthcare programs. France also has a well-defined reimbursement policy for viscosupplements. In France, out of the 13 products available for the treatment of knee osteoarthritis, 12 are reimbursed up to 65% by Social Security. Thus, favorable reimbursement policies with respect to the geriatric population are expected to offer growth opportunities to the key players.

COVID-19 viscosupplementation market impact: 3.0% decline from 2019 to 2020

Recent advancements in R&D of product pipeline provide additional opportunities for the expansion of the market for viscosupplementation. For instance, in April 2018, Bone Therapeutics S.A. completed clinical trials for its product JTA-004 intra-articular injection for knee OA. New products with more efficacious results are also being introduced in the market. For instance, in June 2019, Anika Therapeutics, Inc. showcased its new product Hyalofast, a hyaluronic acid-based scaffold for the repair of cartilages at International Cartilage Regeneration and Joint Preservation Society (ICRS).

Product Insights

Based on product, the market is segmented into single injection, three injections, and five injections. Single-injection emerged as the leading product segment in 2020 with a revenue share of over 45%. The three and five-injection hyaluronic acid viscosupplements have been in the market for quite a long time, whereas the single-injection products are relatively newer. Multiple three injections have been available for the past two decades and have captured a large share of the global market. Three injections are preferred by medical practitioners to help avoid total knee replacement surgery in case of osteoarthritis.

An increasing number of FDA approvals for three-injection viscosupplements is expected to positively impact the segment growth. For instance, in January 2018, OrthogenRx launched TriVisc in the U.S. Demand for single injection products is expected to witness a rise during the forecast period due to a shorter regimen, reduced hospital visits, and fewer adverse effects and associated pain. MONOVISC from Anika Therapeutics is the first single-injection hyaluronic acid from non-animal sources that received FDA approval in early 2014.

End-use Insights

Based on end-use, the market is classified into hospitals and orthopedic clinics/Ambulatory Surgical Centers (ASCs). The orthopedic clinics/ASCs segment held the largest market share of over 61% in 2020 and is also expected to witness the fastest CAGR during the forecast period due to the high demand for outpatient surgeries. ASCs are outpatient surgery centers that focus on offering same-day surgical care, including preventive (surgical) and diagnostic procedures.

ASCs can perform same-day surgeries for ACL surgery, hip, knee, & shoulder replacements, and others. These surgeries are less complicated and require little to no hospitalization. Furthermore, orthopedic clinics are dedicated to the care of the musculoskeletal system. This includes the treatment of surgical and nonsurgical problems involving joints, bones, ligaments, muscles, spine, and nerves. The increasing prevalence of osteoarthritis among the geriatric population is one of the major factors expected to contribute to the growth of this segment.

Viscosupplementation is provided as an outpatient procedure in hospitals and the patient is relieved within a few hours of the procedure. Viscosupplementation procedures performed in a hospital are usually on the recommendation of a general physician or orthopedist of the same hospital. Hospitals are preferred by patients usually in developing countries where orthopedic clinics are scarce. In these countries, where an orthopedic physician is usually a visiting faculty, patients are required to visit the hospital on a specific day. Furthermore, the majority of the multispecialty hospitals worldwide offer viscosupplementation procedures as it does not require any additional investment.

Regional Insights

Asia Pacific accounted for the largest revenue share of more than 45% in 2020 due to the presence of a large geriatric population, which is more susceptible to disorders, such as osteoarthritis. However, Europe is expected to witness the fastest CAGR during the forecast period due to factors, such as the growing geriatric population and increased investments by market players.

Osteoporosis affects more than 2.5 million women in the U.K. and France every year. With the ruling by Haute Autorité de Santé (HAS), 70% of the cost of scan will be covered by the Caisse Primaire d'Assurance Maladie (CPAM). In addition, Haute Autorité de Santé (HAS), the health care body has recommended BONVIVA, which is a medicine prescribed in the U.K. to increase the strength of bones, to have a reimbursement of 65% by the Caisse Primaire d'Assurance Maladie (CPAM).

Growing preference for short treatment regimens, even though high priced, and growing prevalence of target diseases, such as osteoarthritis, are driving the market in North America. In 2016, the most lucrative application of hyaluronic acid in the North America region was in the form of viscosupplements for the management of osteoarthritis. The most consistent growth is anticipated to be exhibited by a single-injection cycle, as it offers convenience compared to its three- and five-injection counterparts.

Key Companies & Market Share Insights

The market is highly competitive as key players are adopting various strategies, such as the launch of products and mergers & acquisitions, to increase their share. For instance, in 2017, Bioventus announced FDA approval of DUROLANE, which is a single-injection HA product for treating the pain associated with knee osteoarthritis. The product was then marketed and being sold in more than 25 nations. Some of the prominent players in the global viscosupplementation market include:

• Sanofi

• Anika Therapeutics, Inc.

• Seikagaku Corp.

• Zimmer Biomet

• Smith & Nephew PLC

• Ferring Pharmaceuticals B.V.

• Lifecore Biomedical

• LG Life Sciences Ltd.

• Fidia Farmaceutici S.p.A

• F.Hoffmann-La Roche Ltd.

Viscosupplementation Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global viscosupplementation market report on the basis of product, end-use, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2028)

  • Single Injection

  • Three Injection

  • Five Injection

• End-use Outlook (Revenue, USD Million, 2016 - 2028)

  • Hospitals

  • Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE